Menu

Archive | .


ASCO 2018: Highlights From the Meeting Through the Lens of a Key Opinion Leader

In this wide ranging interview, Nicholas J. Vogelzang, MD, FASCO, FACP, shares insights, perspectives, and real-world observations from his practice following the 2018 Scientific Sessions of the American Society of Clinical Oncology. Dr Vogelzang serves as Vice Chair of the SWOG GU Committee and is Associate  Director, Genitourinary Research Program, US Oncology Research, Comprehensive Cancer […]

Continue Reading 0

Controversies and Consensus Surrounding Initial Cytoreductive Nephrectomy vs Targeted Therapy: What Is the Optimal Approach?

Michael L. Blute, MD Walter S. Kerr, Jr, Professor of Surgery, Urology Harvard Medical School Chief, Department of Urology Massachusetts General Hospital Boston, Massachusetts   Keywords: cytoreductive nephrectomy, initial, targeted therapy, CARMENA trial, SURTIME, IMDC risk criteria, NCCN guidelines, TKI.   Corresponding Author: Michael L. Blute, Sr, MD, Chief, Department of Urology, Massachusetts General Hospital, […]

Continue Reading 0

Optimizing Benefit and Limiting
Immune-Related Adverse Effects Following Checkpoint Inhibitor Blockade

W. Kimryn Rathmell, MD, PhD Director, Division of Hematology and Oncology Cornelius Abernathy Craig Chair, Department of Medicine Vanderbilt University Medical Center Nashville, Tennessee     Kathryn Eby Beckermann, MD, PhD Clinical Instructor Division of Hematology and Oncology Vanderbilt University Medical Center Nashville, Tennessee     Keywords: immune checkpoint blockade, immune-related adverse effects, checkpoint inhibitors, PD-1, CTLA-4, […]

Continue Reading 0